In this issue:
PD-L1 and TMB as outcomes biomarkers
Osimertinib: Postprogression outcomes in NSCLC
COMMAND-A trial: defactinib in mesothelioma
EGFR-mutant NSCLC transformation to SCLC
Welding fumes and lung cancer risk
Characterising lung cancer in NZ
ICS use might reduce lung cancer risk in COPD
Increasing consultation rates in long-term smokers
A non-invasive test for early-stage lung cancer
Lung cancer with STAS: lobectomy or sublobar resection?
Please login below to download this issue (PDF)